MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1080/09546634.2026.2670906

Медицинская библиотека · The Journal of dermatological treatment · 2026

Stapokibart reduces blood eosinophil counts in patients with moderate-to-severe atopic dermatitis: a post-hoc analysis from phase II and phase III clinical trials.

Zhao Yan, Zhang Furen, Yang Bin, Zhang Litao, Wu Liming, Ding Yangfeng, Wang Jinyan, Li Yumei, Diao Qingchun, Li Jingyi, Sun Qing, Zhu Xiaohong, Man Xiaoyong, Wang Lihua, Feng Yanyan, Cai Tao, Zeng Huiming, Li Linfeng, Lu Jianyun, Ren Hong, Li Fuqiu, Lu Qianjin, Tao Xiaohua, Xiao Rong, Zhang Chunlei, Xia Xiujuan, Cheng Hao, Ji Chao, Zhao Wenjie, Qiu Yanping, Chu Wei, Yan Hongyue, Chen Bo, Zhang Jianzhong

СтатьяРандомизированное исследованиеКлиническое исследование III фазыКлиническое исследование II фазыПеревод в очереди

Аннотация

BACKGROUND

Eosinophils are involved in the pathogenesis of atopic dermatitis (AD).

OBJECTIVE

This post-hoc analysis evaluated the effect of stapokibart on blood eosinophil counts in moderate-to-severe AD patients.

METHODS

The phase II AD002 trial (n = 120) randomly assigned patients to stapokibart 300 mg every 2 weeks (Q2W), 150 mg Q2W, or placebo for 16 weeks. The phase III AD005 trial (n = 500) randomly assigned patients to stapokibart 300 mg Q2W or placebo for 16 weeks, followed by open-label stapokibart 300 mg Q2W for 36 weeks. Efficacy and safety were analyzed in subgroups stratified by baseline blood eosinophil counts (≥500 or <500 cells/µL).

RESULTS

Stapokibart treatment resulted in sustained reductions in blood eosinophil counts versus placebo (baseline vs. Week 16: high-dose 420 vs. 235 cells/μL, low-dose 530 vs. 315 cells/μL in AD002; 370 vs. 210 cells/μL in AD005). Furthermore, stapokibart demonstrated superior efficacy over placebo in achieving higher Eczema Area and Severity Index (EASI)-75 response rates at Week 16 in both eosinophil subgroups. The incidence of adverse events was similar across eosinophil subgroups, with most events being mild or moderate.

CONCLUSION

Stapokibart reduced blood eosinophil counts in AD patients and demonstrated favorable efficacy and safety regardless of baseline blood eosinophil counts.

Для цитирования: Zhao Yan, Zhang Furen, Yang Bin, Zhang Litao, Wu Liming, Ding Yangfeng, Wang Jinyan, Li Yumei, Diao Qingchun, Li Jingyi, Sun Qing, Zhu Xiaohong, Man Xiaoyong, Wang Lihua, Feng Yanyan, Cai Tao, Zeng Huiming, Li Linfeng, Lu Jianyun, Ren Hong, Li Fuqiu, Lu Qianjin, Tao Xiaohua, Xiao Rong, Zhang Chunlei, Xia Xiujuan, Cheng Hao, Ji Chao, Zhao Wenjie, Qiu Yanping, Chu Wei, Yan Hongyue, Chen Bo, Zhang Jianzhong. Stapokibart reduces blood eosinophil counts in patients with moderate-to-severe atopic dermatitis: a post-hoc analysis from phase II and phase III clinical trials.. The Journal of dermatological treatment. 2026. DOI: 10.1080/09546634.2026.2670906.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.